Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) EBT Margin (2016 - 2025)

Coherus Oncology's EBT Margin history spans 12 years, with the latest figure at 363.56% for Q4 2025.

  • For Q4 2025, EBT Margin rose 23249.0% year-over-year to 363.56%; the TTM value through Dec 2025 reached 434.23%, down 23697.0%, while the annual FY2025 figure was 434.23%, 38200.0% up from the prior year.
  • EBT Margin for Q4 2025 was 363.56% at Coherus Oncology, up from 384.73% in the prior quarter.
  • Across five years, EBT Margin topped out at 15.19% in Q3 2024 and bottomed at 2947.83% in Q1 2024.
  • The 5-year median for EBT Margin is 175.3% (2022), against an average of 363.19%.
  • The largest annual shift saw EBT Margin tumbled -271436bps in 2024 before it surged 232409bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 62.28% in 2021, then plummeted by -108bps to 129.81% in 2022, then skyrocketed by 33bps to 87.03% in 2023, then plummeted by -585bps to 596.06% in 2024, then skyrocketed by 39bps to 363.56% in 2025.
  • Per Business Quant, the three most recent readings for CHRS's EBT Margin are 363.56% (Q4 2025), 384.73% (Q3 2025), and 437.51% (Q2 2025).